Jose Munoz-Olaya
Chief Scientific Officer Valink Therapeutics
Seminars
Wednesday 1st April 2026
Biomarker-Driven Development of Multispecific ADCs: From Target Qualification to Patient Stratification
12:00 pm
- How biomarker-driven target qualification, internalisation kinetics, and payload sensitivity shape the success or failure of modern ADCs
- Practical approaches to stratifying patients in heterogeneous tumours
- Translational biomarkers that link target biology with payload exposure – enabling better dose selection, early efficacy signals, and rational design of multispecific ADCs
